Learn More
BACKGROUND The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer. METHODS Real-time polymerase chain reaction analysis of 742 miRs was performed using plasma-derived circulating microvesicles of 78(More)
373 Background: Microvesicles are principally derived either from the endosomal pathway (as exosomes) or shed directly from the plasma membrane. They are between 40-500 nm in diameter and are secreted by most cell types, including tumor cells. In circulation, microvesicles appear to participate in cellular communication by transporting mRNAs, miRs and(More)
4626 Background: Attempts to find a blood-based biomarker for prostate cancer (PCa) detection have been challenging. Quantification of microRNAs (miRs) in blood may identify potential genetic biomarkers. Using plasma-derived circulating microvesicles (cMV) as an enriched source of miRs from cells, we sought a miR biosignature that could distinguish PCa(More)
TPS248 Background: Neoadjuvant chemotherapy (NAC) is a common approach to the treatment of women with locally advanced and inflammatory breast cancers. It is becoming utilized in women with palpable and operable tumors >/= 2cm. The rate of response to NAC varies widely and ranges from 2-80%. It may be useful to have markers to determine which patients are(More)
e15172 Background: Circulating microvesicles (cMV) are small membrane bound particles ranging from 30 to 1000 nm in diameter secreted by many cell types, including tumor cells. The quantity and biomarker composition of cMV can be used to detect and monitor the presence of disease. A cMV biosignature composed of 6 surface biomarkers, the tetraspanins CD9,(More)
  • 1